Tags : Idacio

Fresenius Kabi Signs an Agreement with Medec to Commercialize IDACIO

Shots: Fresenius Kabi and Medec collaborated to offer IDACIO as an additional therapy option for rheumatologists and dermatologists to treat rheumatic illnesses. From Jun 01, 2020, Medec’s will market the biosimilar therapy Last year, Fresenius Kabi launched IDACIO in the EU for arthritis and psoriasis. The collaboration offers patients and doctors new benefits and synergies […]Read More

Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in

Shots: The approval is based on its non-inferiority data consisting of its PK, efficacy, safety, immunogenicity data with the reference product in analytical, preclinical and clinical data trials Fresenius Kabi has a portfolio consisting of generic drugs, infusion therapies, biosimilars, and clinical nutrition products focusing on multiple therapy areas Idacio (adalimumab, biosimilar) is a mAb […]Read More